Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 102


Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60-75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study.

Ustun C, Le-Rademacher J, Wang HL, Othus M, Sun Z, Major B, Zhang MJ, Storrick E, Lafky JM, Chow S, Mrózek K, Attar EC, Nand S, Bloomfield CD, Cripe LD, Tallman MS, Appelbaum F, Larson RA, Marcucci G, Roboz GJ, Uy GL, Stone RM, Jatoi A, Shea TC, de Lima M, Foran JM, Sandmaier BM, Litzow MR, Erba HP, Hurria A, Weisdorf DJ, Artz AS.

Leukemia. 2019 May 9. doi: 10.1038/s41375-019-0477-x. [Epub ahead of print]


Diagnostic utility of bronchoscopy in adults with acute myeloid leukemia and other high-grade myeloid neoplasms.

Buckley SA, Mark NM, Othus M, Estey EH, Patel K, Walter RB.

Leuk Lymphoma. 2019 Mar 11:1-4. doi: 10.1080/10428194.2019.1581933. [Epub ahead of print] No abstract available.


Pre-transplant bone marrow monocytic myeloid-derived suppressor cell frequency is not associated with outcome after allogeneic hematopoietic cell transplantation for acute myeloid leukemia in remission.

Godwin CD, Fromm JR, Othus M, Sandmaier BM, Mielcarek MB, Wood BL, Appelbaum FR, Storb R, Walter RB.

Bone Marrow Transplant. 2019 Sep;54(9):1511-1514. doi: 10.1038/s41409-019-0481-9. Epub 2019 Feb 25. No abstract available.


The relationship between clinical trial accrual volume and outcomes in acute myeloid leukemia: A SWOG/ECOG-ACRIN study (S0106 and E1900).

Medeiros BC, Othus M, Tallman MS, Sun Z, Fernandez HF, Rowe JM, Lazarus HM, Appelbaum FR, Luger SM, Litzow MR, Erba HP.

Leuk Res. 2019 Mar;78:29-33. doi: 10.1016/j.leukres.2019.01.007. Epub 2019 Jan 17.


New study-designs to address the clinical complexity of acute myeloid leukemia.

Estey E, Othus M, Gale RP.

Leukemia. 2019 Mar;33(3):567-569. doi: 10.1038/s41375-018-0363-y. Epub 2019 Jan 22. No abstract available.


Phase I/II trial of cladribine, high-dose cytarabine, mitoxantrone, and G-CSF with dose-escalated mitoxantrone for relapsed/refractory acute myeloid leukemia and other high-grade myeloid neoplasms.

Halpern AB, Othus M, Huebner EM, Scott BL, Hendrie PC, Percival MM, Becker PS, Smith HA, Oehler VG, Orozco JJ, Cassaday RD, Gardner KM, Chen TL, Buckley SA, Orlowski KF, Anwar A, Estey EH, Walter RB.

Haematologica. 2019 Apr;104(4):e143-e146. doi: 10.3324/haematol.2018.204792. Epub 2018 Nov 8. No abstract available.


Relative survival following response to 7 + 3 versus azacytidine is similar in acute myeloid leukemia and high-risk myelodysplastic syndromes: an analysis of four SWOG studies.

Othus M, Sekeres MA, Nand S, Garcia-Manero G, Appelbaum FR, Erba HP, Estey E.

Leukemia. 2019 Feb;33(2):371-378. doi: 10.1038/s41375-018-0275-x. Epub 2018 Oct 12.


Second cycle remission achievement with 7+3 and survival in adults with newly diagnosed acute myeloid leukemia: analysis of recent SWOG trials.

Othus M, Estey EH, Garcia-Manero G, Wood BL, Stirewalt DL, Godwin JE, Weick JK, Anderson JE, Appelbaum FR, Erba HP, Walter RB.

Leukemia. 2019 Feb;33(2):554-558. doi: 10.1038/s41375-018-0274-y. Epub 2018 Oct 12. No abstract available.


A comparison of patients with acute myeloid leukemia and high-risk myelodysplastic syndrome treated on versus off study.

Buckley SA, Percival ME, Othus M, Halpern AB, Huebner EM, Becker PS, Shaw C, Shadman M, Walter RB, Estey EH.

Leuk Lymphoma. 2019 Apr;60(4):1023-1029. doi: 10.1080/10428194.2018.1516036. Epub 2018 Oct 2.


Phase 1/2 trial of GCLAM with dose-escalated mitoxantrone for newly diagnosed AML or other high-grade myeloid neoplasms.

Halpern AB, Othus M, Huebner EM, Scott BL, Becker PS, Percival MM, Hendrie PC, Gardner KM, Chen TL, Buckley SA, Orlowski KF, Anwar A, Appelbaum FR, Erba HP, Estey EH, Walter RB.

Leukemia. 2018 Nov;32(11):2352-2362. doi: 10.1038/s41375-018-0135-8. Epub 2018 Apr 17.


Deep NPM1 Sequencing Following Allogeneic Hematopoietic Cell Transplantation Improves Risk Assessment in Adults with NPM1-Mutated AML.

Zhou Y, Othus M, Walter RB, Estey EH, Wu D, Wood BL.

Biol Blood Marrow Transplant. 2018 Aug;24(8):1615-1620. doi: 10.1016/j.bbmt.2018.04.017. Epub 2018 Apr 21.


Comparable outcomes of patients eligible vs ineligible for SWOG leukemia studies.

Statler A, Othus M, Erba HP, Chauncey TR, Radich JP, Coutre S, Advani A, Nand S, Ravandi F, Mukherjee S, Sekeres MA.

Blood. 2018 Jun 21;131(25):2782-2788. doi: 10.1182/blood-2018-01-826693. Epub 2018 Apr 4.


Report of the relapsed/refractory cohort of SWOG S0919: A phase 2 study of idarubicin and cytarabine in combination with pravastatin for acute myelogenous leukemia (AML).

Advani AS, Li H, Michaelis LC, Medeiros BC, Liedtke M, List AF, O'Dwyer K, Othus M, Erba HP, Appelbaum FR.

Leuk Res. 2018 Apr;67:17-20. doi: 10.1016/j.leukres.2018.01.021. Epub 2018 Jan 31.


Unsatisfactory efficacy in randomized study of reduced-dose CPX-351 for medically less fit adults with newly diagnosed acute myeloid leukemia or other high-grade myeloid neoplasm.

Walter RB, Othus M, Orlowski KF, McDaniel EN, Scott BL, Becker PS, Percival MM, Hendrie PC, Medeiros BC, Chiarella MT, Louie AC, Estey EH.

Haematologica. 2018 Mar;103(3):e106-e109. doi: 10.3324/haematol.2017.182642. Epub 2017 Dec 14. No abstract available.


Impact of Specimen Heterogeneity on Biomarkers in Repository Samples from Patients with Acute Myeloid Leukemia: A SWOG Report.

Pogosova-Agadjanyan EL, Moseley A, Othus M, Appelbaum FR, Chauncey TR, Chen IL, Erba HP, Godwin JE, Fang M, Kopecky KJ, List AF, Pogosov GL, Radich JP, Willman CL, Wood BL, Meshinchi S, Stirewalt DL.

Biopreserv Biobank. 2018 Feb;16(1):42-52. doi: 10.1089/bio.2017.0079. Epub 2017 Nov 27. Erratum in: Biopreserv Biobank. 2018 Apr;16(2):168.


Intergroup LEAP trial (S1612): A randomized phase 2/3 platform trial to test novel therapeutics in medically less fit older adults with acute myeloid leukemia.

Walter RB, Michaelis LC, Othus M, Uy GL, Radich JP, Little RF, Hita S, Saini L, Foran JM, Gerds AT, Klepin HD, Hay AE, Assouline S, Lancet JE, Couban S, Litzow MR, Stone RM, Erba HP.

Am J Hematol. 2018 Feb;93(2):E49-E52. doi: 10.1002/ajh.24980. Epub 2017 Dec 4. No abstract available.


US Intergroup Study of Chemotherapy Plus Dasatinib and Allogeneic Stem Cell Transplant in Philadelphia Chromosome Positive ALL.

Ravandi F, Othus M, O'Brien SM, Forman SJ, Ha CS, Wong JYC, Tallman MS, Paietta E, Racevskis J, Uy GL, Horowitz M, Takebe N, Little R, Borate U, Kebriaei P, Kingsbury L, Kantarjian HM, Radich JP, Erba HP, Appelbaum FR.

Blood Adv. 2016 Dec 27;1(3):250-259. doi: 10.1182/bloodadvances.2016001495.


High frequency of brain metastases after adjuvant therapy for high-risk melanoma.

Samlowski WE, Moon J, Witter M, Atkins MB, Kirkwood JM, Othus M, Ribas A, Sondak VK, Flaherty LE.

Cancer Med. 2017 Nov;6(11):2576-2585. doi: 10.1002/cam4.1223. Epub 2017 Oct 10.


Quality of life from the perspective of the patient with acute myeloid leukemia.

Buckley SA, Jimenez-Sahagun D, Othus M, Walter RB, Lee SJ.

Cancer. 2018 Jan 1;124(1):145-152. doi: 10.1002/cncr.30982. Epub 2017 Sep 7.


Mitoxantrone, etoposide and cytarabine following epigenetic priming with decitabine in adults with relapsed/refractory acute myeloid leukemia or other high-grade myeloid neoplasms: a phase 1/2 study.

Halpern AB, Othus M, Huebner EM, Buckley SA, Pogosova-Agadjanyan EL, Orlowski KF, Scott BL, Becker PS, Hendrie PC, Chen TL, Percival MM, Estey EH, Stirewalt DL, Walter RB.

Leukemia. 2017 Dec;31(12):2560-2567. doi: 10.1038/leu.2017.165. Epub 2017 May 30.


Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117.

Sekeres MA, Othus M, List AF, Odenike O, Stone RM, Gore SD, Litzow MR, Buckstein R, Fang M, Roulston D, Bloomfield CD, Moseley A, Nazha A, Zhang Y, Velasco MR, Gaur R, Atallah E, Attar EC, Cook EK, Cull AH, Rauh MJ, Appelbaum FR, Erba HP.

J Clin Oncol. 2017 Aug 20;35(24):2745-2753. doi: 10.1200/JCO.2015.66.2510. Epub 2017 May 9.


Assessing treatment efficacy in the subset of responders in a randomized clinical trial.

Korn EL, Othus M, Chen T, Freidlin B.

Ann Oncol. 2017 Jul 1;28(7):1640-1647. doi: 10.1093/annonc/mdx197.


Accounting for Cured Patients in Cost-Effectiveness Analysis.

Othus M, Bansal A, Koepl L, Wagner S, Ramsey S.

Value Health. 2017 Apr;20(4):705-709. doi: 10.1016/j.jval.2016.04.011. Epub 2016 Jun 9.


Flow cytometric demonstration of decrease in bone marrow leukemic blasts after 'Day 14' without further therapy in acute myeloid leukemia.

Chen X, Othus M, Wood BL, Walter RB, Percival MM, Becker PS, Hendrie PC, Appelbaum FR, Estey EH.

Leuk Lymphoma. 2017 Nov;58(11):2717-2719. doi: 10.1080/10428194.2017.1307359. Epub 2017 Mar 28. No abstract available.


Prognostic methylation markers for overall survival in cytogenetically normal patients with acute myeloid leukemia treated on SWOG trials.

Qu X, Othus M, Davison J, Wu Y, Yan L, Meshinchi S, Ostronoff F, Estey EH, Radich JP, Erba HP, Appelbaum FR, Fang M.

Cancer. 2017 Jul 1;123(13):2472-2481. doi: 10.1002/cncr.30626. Epub 2017 Feb 21.


Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis.

Buckley SA, Wood BL, Othus M, Hourigan CS, Ustun C, Linden MA, DeFor TE, Malagola M, Anthias C, Valkova V, Kanakry CG, Gruhn B, Buccisano F, Devine B, Walter RB.

Haematologica. 2017 May;102(5):865-873. doi: 10.3324/haematol.2016.159343. Epub 2017 Jan 25. Review.


Determinants of fatal bleeding during induction therapy for acute promyelocytic leukemia in the ATRA era.

Mantha S, Goldman DA, Devlin SM, Lee JW, Zannino D, Collins M, Douer D, Iland HJ, Litzow MR, Stein EM, Appelbaum FR, Larson RA, Stone R, Powell BL, Geyer S, Laumann K, Rowe JM, Erba H, Coutre S, Othus M, Park JH, Wiernik PH, Tallman MS.

Blood. 2017 Mar 30;129(13):1763-1767. doi: 10.1182/blood-2016-10-747170. Epub 2017 Jan 12.


Next-Generation Sequencing in Adult B Cell Acute Lymphoblastic Leukemia Patients.

Sala Torra O, Othus M, Williamson DW, Wood B, Kirsch I, Robins H, Beppu L, O'Donnell MR, Forman SJ, Appelbaum FR, Radich JP.

Biol Blood Marrow Transplant. 2017 Apr;23(4):691-696. doi: 10.1016/j.bbmt.2016.12.639. Epub 2017 Jan 3.


Assessment of Minimal Residual Disease in Standard-Risk AML.

Othus M, Estey E, Gale RP.

N Engl J Med. 2016 Aug 11;375(6):e9. doi: 10.1056/NEJMc1603847. No abstract available.


Infusion of a non-HLA-matched ex-vivo expanded cord blood progenitor cell product after intensive acute myeloid leukaemia chemotherapy: a phase 1 trial.

Delaney C, Milano F, Cicconi L, Othus M, Becker PS, Sandhu V, Nicoud I, Dahlberg A, Bernstein ID, Appelbaum FR, Estey EH.

Lancet Haematol. 2016 Jul;3(7):e330-9. doi: 10.1016/S2352-3026(16)30023-0. Epub 2016 Jun 7.


Clinical Experience With Modified, Single-Tube T-Cell Receptor Vβ Flow Cytometry Analysis for T-Cell Clonality.

Wu D, Anderson MM, Othus M, Wood BL.

Am J Clin Pathol. 2016 Apr;145(4):467-85. doi: 10.1093/ajcp/aqw015.


Information time scales for interim analyses of randomized clinical trials.

Freidlin B, Othus M, Korn EL.

Clin Trials. 2016 Aug;13(4):391-9. doi: 10.1177/1740774516644752. Epub 2016 May 2.


Effect of measurable ('minimal') residual disease (MRD) information on prediction of relapse and survival in adult acute myeloid leukemia.

Othus M, Wood BL, Stirewalt DL, Estey EH, Petersdorf SH, Appelbaum FR, Erba HP, Walter RB.

Leukemia. 2016 Oct;30(10):2080-2083. doi: 10.1038/leu.2016.120. Epub 2016 May 2. No abstract available.


Prediction of CR following a second course of '7+3' in patients with newly diagnosed acute myeloid leukemia not in CR after a first course.

Othus M, Mukherjee S, Sekeres MA, Godwin J, Petersdorf S, Appelbaum FR, Erba H, Estey E.

Leukemia. 2016 Aug;30(8):1779-80. doi: 10.1038/leu.2016.48. Epub 2016 Feb 29. No abstract available.


Relationship between event-free survival and overall survival in acute myeloid leukemia: a report from SWOG, HOVON/SAKK, and MRC/NCRI.

Othus M, van Putten W, Lowenberg B, Petersdorf SH, Nand S, Erba H, Appelbaum F, Hills R, Russell N, Burnett A, Estey E.

Haematologica. 2016 Jul;101(7):e284-6. doi: 10.3324/haematol.2015.138552. Epub 2016 Mar 24. No abstract available.


Pre- and post-transplant quantification of measurable ('minimal') residual disease via multiparameter flow cytometry in adult acute myeloid leukemia.

Zhou Y, Othus M, Araki D, Wood BL, Radich JP, Halpern AB, Mielcarek M, Estey EH, Appelbaum FR, Walter RB.

Leukemia. 2016 Jul;30(7):1456-64. doi: 10.1038/leu.2016.46. Epub 2016 Feb 29.


Association between early promoter-specific DNA methylation changes and outcome in older acute myeloid leukemia patients.

Achille NJ, Othus M, Phelan K, Zhang S, Cooper K, Godwin JE, Appelbaum FR, Radich JP, Erba HP, Nand S, Zeleznik-Le NJ.

Leuk Res. 2016 Mar;42:68-74. doi: 10.1016/j.leukres.2016.01.004. Epub 2016 Jan 15.


Prediction of early death in adults with relapsed or refractory acute myeloid leukemia.

Godwin CD, Othus M, Powell MA, Buckley SA, Estey EH, Walter RB.

Leuk Lymphoma. 2016 Oct;57(10):2421-4. doi: 10.3109/10428194.2015.1135436. Epub 2016 Jan 11. No abstract available.


Does outcome of second salvage therapy in relapsed or refractory acute myeloid leukemia depend on intensity of either first or second salvage therapy?

Araki D, Othus M, Walter RB, Becker PS, Sandhu V, Estey EH.

Leuk Lymphoma. 2016 May;57(5):1205-7. doi: 10.3109/10428194.2015.1079316. Epub 2015 Dec 23. No abstract available.


New drug approvals in acute myeloid leukemia: what's the best end point?

Estey E, Othus M, Lee SJ, Appelbaum FR, Gale RP.

Leukemia. 2016 Mar;30(3):521-5. doi: 10.1038/leu.2015.262. Epub 2015 Dec 18. No abstract available.


Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia: Time to Move Toward a Minimal Residual Disease-Based Definition of Complete Remission?

Araki D, Wood BL, Othus M, Radich JP, Halpern AB, Zhou Y, Mielcarek M, Estey EH, Appelbaum FR, Walter RB.

J Clin Oncol. 2016 Feb 1;34(4):329-36. doi: 10.1200/JCO.2015.63.3826. Epub 2015 Dec 14.


Resource Utilization and Safety of Outpatient Management Following Intensive Induction or Salvage Chemotherapy for Acute Myeloid Leukemia or Myelodysplastic Syndrome: A Nonrandomized Clinical Comparative Analysis.

Vaughn JE, Othus M, Powell MA, Gardner KM, Rizzuto DL, Hendrie PC, Becker PS, Pottinger PS, Estey EH, Walter RB.

JAMA Oncol. 2015 Nov;1(8):1120-7. doi: 10.1001/jamaoncol.2015.2969.


Empiric definition of eligibility criteria for clinical trials in relapsed/refractory acute myeloid leukemia: analysis of 1,892 patients from HOVON/SAKK and SWOG.

Walter RB, Othus M, Löwenberg B, Ossenkoppele GJ, Petersdorf SH, Pabst T, Vekemans MC, Appelbaum FR, Erba HP, Estey EH.

Haematologica. 2015 Oct;100(10):e409-11. doi: 10.3324/haematol.2015.130013. Epub 2015 Jul 9. No abstract available.


Effect of allogeneic hematopoietic cell transplantation in first complete remission on post-relapse complete remission rate and survival in acute myeloid leukemia.

Araki D, Othus M, Walter RB, Sandhu V, Sandmaier BM, Becker PS, Appelbaum FR, Estey EH.

Haematologica. 2015 Jul;100(7):e254-6. doi: 10.3324/haematol.2014.118570. Epub 2015 Mar 20. No abstract available.


Effect of genetic profiling on prediction of therapeutic resistance and survival in adult acute myeloid leukemia.

Walter RB, Othus M, Paietta EM, Racevskis J, Fernandez HF, Lee JW, Sun Z, Tallman MS, Patel J, Gönen M, Abdel-Wahab O, Levine RL, Estey EH.

Leukemia. 2015 Oct;29(10):2104-7. doi: 10.1038/leu.2015.76. Epub 2015 Mar 16. No abstract available.


Elevated lymphocyte count at time of acute myeloid leukemia diagnosis is associated with shorter remission.

Bar M, Othus M, Park HM, Sandhu V, Chen X, Wood BL, Estey E.

Leuk Lymphoma. 2015;56(11):3109-15. doi: 10.3109/10428194.2015.1020060. Epub 2015 May 12.


Prognostic significance of NPM1 mutations in the absence of FLT3-internal tandem duplication in older patients with acute myeloid leukemia: a SWOG and UK National Cancer Research Institute/Medical Research Council report.

Ostronoff F, Othus M, Lazenby M, Estey E, Appelbaum FR, Evans A, Godwin J, Gilkes A, Kopecky KJ, Burnett A, List AF, Fang M, Oehler VG, Petersdorf SH, Pogosova-Agadjanyan EL, Radich JP, Willman CL, Meshinchi S, Stirewalt DL.

J Clin Oncol. 2015 Apr 1;33(10):1157-64. doi: 10.1200/JCO.2014.58.0571. Epub 2015 Feb 23. Erratum in: J Clin Oncol. 2015 May 20;33(15):1715.


The treatment-related mortality score is associated with non-fatal adverse events following intensive AML induction chemotherapy.

Buckley SA, Othus M, Estey EH, Walter RB.

Blood Cancer J. 2015 Jan 30;5:e276. doi: 10.1038/bcj.2014.97. No abstract available.


Central nervous system involvement in acute myeloid leukemia patients undergoing hematopoietic cell transplantation.

Bar M, Tong W, Othus M, Loeb KR, Estey EH.

Biol Blood Marrow Transplant. 2015 Mar;21(3):546-51. doi: 10.1016/j.bbmt.2014.11.683. Epub 2014 Dec 26.


G-CSF priming, clofarabine, and high dose cytarabine (GCLAC) for upfront treatment of acute myeloid leukemia, advanced myelodysplastic syndrome or advanced myeloproliferative neoplasm.

Becker PS, Medeiros BC, Stein AS, Othus M, Appelbaum FR, Forman SJ, Scott BL, Hendrie PC, Gardner KM, Pagel JM, Walter RB, Parks C, Wood BL, Abkowitz JL, Estey EH.

Am J Hematol. 2015 Apr;90(4):295-300. doi: 10.1002/ajh.23927. Epub 2015 Jan 30.

Supplemental Content

Support Center